| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $147,968,430 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DC023331 | COCHLEAR SIGNALING MEDIATED BY HENSEN’S CELLS | 000 | 1 | NIH | 6/11/2026 | $438,859 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA311275 | Systemic crosstalk between tumor cells and neutrophils in triple-negative breast cancer | 000 | 1 | NIH | 7/30/2026 | $390,453 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AI200941 | Mechanism of cross-reaction and cross-protection for Mayaro virus elicited by chikungunya vaccine | 000 | 1 | NIH | 7/24/2026 | $802,421 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30AG099336 | Selective Targeting of Myeloid-derived APOE to improve safety and efficacy of anti-amyloid antibody therapy in Alzheimer’s Disease | 000 | 1 | NIH | 6/18/2026 | $38,914 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086163 | Slow and Fast Myosin Binding Protein-C in Human Skeletal Muscles | 000 | 1 | NIH | 7/29/2026 | $87,195 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086163 | Slow and Fast Myosin Binding Protein-C in Human Skeletal Muscles | 000 | 1 | NIH | 7/29/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30AG099336 | Selective Targeting of Myeloid-derived APOE to improve safety and efficacy of anti-amyloid antibody therapy in Alzheimer’s Disease | 001 | 1 | NIH | 6/18/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R03DE035681 | Elucidating the etiology for Schneckenbecken dysplasia, a rare disease, using a vetrebrate model system | 000 | 1 | NIH | 2/17/2026 | $154,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA064646 | Evaluation of the Combination Muscarinic Cholinergic Receptor Drug Product Cobenfy as a Medication for Cocaine Use Disorder Using Translational Human and Rat Cocaine Choice Procedures | 000 | 1 | NIH | 5/1/2026 | $663,978 |
| | 2026 | 2026 | University of Kentucky Research Foundation, The | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | 90DDUC0145 | University Centers for Excellence in Developmental Disabilities | 00 | 4 | ACL | 7/1/2026 | $629,042 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 002 | 2 | NIH | 4/29/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 001 | 2 | NIH | 4/7/2026 | $84,564 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082339 | Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia | 000 | 2 | NIH | 3/26/2026 | $515,737 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA062746 | Impact of Cannabis on Opioid Self-Administration: Determining if Cannabis Alters the Drive to Take Opioids in Individuals with Opioid Use Disorder | 000 | 1 | NIH | 2/4/2026 | $647,142 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | UK955657 | Rural Maternity and Obstetrics Management Strategies Program | 01 | 1 | HRSA | 9/1/2026 | $0 |
| | 2026 | 2026 | University of Kentucky Research Foundation, The | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | UK955657 | Rural Maternity and Obstetrics Management Strategies Program | 00 | 1 | HRSA | 7/16/2026 | $897,158 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS142462 | Improving Disease-Modifying Therapy Uptake among Patients with Multiple Sclerosis | 000 | 1 | NIH | 6/19/2026 | $662,969 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R34CA313778 | Planning grant to support a future trial of an intervention to improve clinical trial education and enrollment | 000 | 1 | NIH | 6/19/2026 | $281,820 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI197062 | Switches controlling bacteriophage lysis of the Lyme disease spirochete | 000 | 1 | NIH | 2/18/2026 | $420,063 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098189 | Decoding the Muscle Epitranscriptome: Deep Learning Detection of RNA Modifications in Aging Muscle | 000 | 1 | NIH | 1/21/2026 | $616,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098743 | Arginine Sensor (CASTOR1) Dysfunction Drives Tauopathy | 000 | 1 | NIH | 1/21/2026 | $423,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG097476 | RETURN: RECOVERY TO PHYSICALFUNCTION AFTER CRITICAL ILLNESS IN OLDER ADULTS | 001 | 1 | NIH | 8/14/2026 | $72,922 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG097476 | RETURN: RECOVERY TO PHYSICALFUNCTION AFTER CRITICAL ILLNESS IN OLDER ADULTS | 000 | 1 | NIH | 1/30/2026 | $382,830 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 001 | 4 | NIH | 2/6/2026 | $67,776 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 000 | 4 | NIH | 1/26/2026 | $610,002 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD116429 | The role of glucocorticoid receptor in the ovary | 000 | 2 | NIH | 5/28/2026 | $643,408 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25AG092311 | Kentucky Postbaccalaureate Alzheimer’s Disease Research Education Program (KYPAD) | 000 | 2 | NIH | 6/18/2026 | $418,309 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS136272 | Harnessing engineered drug-free polymeric nanoformulations to reprogram innate immune cells for spinal trauma | 000 | 3 | NIH | 3/3/2026 | $326,594 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P01AG078116 | Strategies for targeting astrocyte reactivity in Alzheimer's disease and related dementias | 000 | 5 | NIH | 7/3/2026 | $3,985,231 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | UH3NS134920 | Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning | 000 | 4 | NIH | 9/10/2026 | $643,949 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084850 | Regulation of Myonuclear Turnover Dynamics in Multinucleated Muscle Cells | 000 | 2 | NIH | 6/12/2026 | $529,010 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG092253 | Feasibility, Acceptability, and Preliminary Efficacy of an HIV Prevention Intervention for Older Black Women | 000 | 2 | NIH | 8/18/2026 | $126,015 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG093616 | Evaluation of Noninvasive Muscle Imaging Biomarkers for Knee Osteoarthritis in Older Adults | 000 | 1 | NIH | 1/23/2026 | $666,504 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R03CA308625 | Fatty Acid Synthase Driven Exosome Secretion in Colorectal Cancer Metastasis | 000 | 1 | NIH | 6/9/2026 | $154,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS147149 | Repetitive Mild TBI and Physiological Stress as Catalysts for Chronic Neurovascular Dysfunction | 000 | 1 | NIH | 1/26/2026 | $192,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | RM1DA064496 | Kentucky Women's Justice Community Overdose Innovation Network - Phase II | 002 | 2 | NIH | 6/30/2026 | $1,439,775 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA307890 | Single Cell-Resolution Imaging of Drug Resistance via Toxic Metal Pre-exposure in Lung Patient Tumor Microenvironment | 000 | 1 | NIH | 6/12/2026 | $395,973 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084134 | Biomarkers to Track Effective Interventions that Delay Dementia Onset in Participants of the "Risk Reduction for Alzheimer's Disease (rrAD)" Trial | 000 | 2 | NIH | 8/31/2026 | $742,367 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086367 | Nutrient sensing and cell fate determination through structural allostery in PASK | 000 | 1 | NIH | 9/1/2026 | $294,652 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL177556 | Targeting NINJ1-mediated Plasma Membrane Rupture to Prevent Thrombosis | 000 | 2 | NIH | 8/7/2026 | $528,032 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086367 | Nutrient sensing and cell fate determination through structural allostery in PASK | 000 | 1 | NIH | 9/1/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21DA065417 | Preserving Respiratory Motor Function and Plasticity with Opioid Receptor Acting Agonists | 000 | 1 | NIH | 9/8/2026 | $231,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K12TR006378 | CTSA K12 Program at the University of Kentucky | 000 | 1 | NIH | 9/7/2026 | $756,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140312 | Targeting Intracellular Cholesterol Distribution: Mechanisms and Therapeutic Strategies for Metabolic dysfunction-associated steatotic liver disease (MASLD) | 000 | 1 | NIH | 3/11/2026 | $707,062 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K99NS150925 | Clinical Prediction, Genetic Architecture, and Environmental Modification in Alzheimer’s Disease, LATE, and Mixed Pathology | 000 | 1 | NIH | 9/3/2026 | $124,945 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32TR006369 | CTSA Predoctoral T32 at the University of Kentucky | 000 | 1 | NIH | 9/7/2026 | $230,852 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG100290 | Emerging Role of GPRC6a Variants in Alzheimer’s disease and Tauopathies | 000 | 1 | NIH | 9/9/2026 | $296,688 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG100290 | Emerging Role of GPRC6a Variants in Alzheimer’s disease and Tauopathies | 000 | 1 | NIH | 9/9/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | UM1TR006383 | Kentucky Center for Clinical and Translational Science | 000 | 1 | NIH | 9/3/2026 | $4,004,255 |
|
